At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Feladilimab for Neoplasms. Completed, enrolled 105 participants across 43 sites in 12 countries.
Detailed Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesCanada, France, Germany, Italy, Netherlands, Poland, Romania, Russia, South Korea, Spain, Sweden, United States
CollaboratorsiTeos Belgium SA
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
Primary CompletionSep 2021
First PostedSep 2022
TodayJul 2026
First PostedSep 23, 2022
Enrollment StartJan 24, 2019
Primary CompletionSep 23, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 3.8 years ago
Interventions
Docetaxeldrug
Docetaxel was administered as IV infusion.
Feladilimabdrug
Feladilimab was administered as IV infusion.